Table 3 Anti-angiogenic treatments
From: Outcome of patients with advanced solitary fibrous tumors: the Centre Léon Bérard experience
Patient | Treatment | Line | Best response | PFS (months) | OS (months) |
|---|---|---|---|---|---|
1 | Sunitinib | 4 | SD | 30 | 34 |
2 | Pazopanib | 3 | SD | 8 | 15 |
3 | Pazopanib | 2 | PD | 2 | 4 |
4 | Sunitinib | 4 | PD | 2 | 5 |
5 | Pazopanib | 2 | SD | 14 | 19 |
6 | Pazopanib | 2 | PD | 0,3 | 0,3 |
7 | Pazopanib | 3 | PD | 2 | 5 |
8 | Sunitinib | 2 | SD | 2 | 33 |
9 | Sunitinib | 2 | SD | 30 | 50 |
10 | Pazopanib | 2 | PD | 4 | 34 |